d4T (Stavudine, Zerit): Research
- Prospective Study of Hyperlipidemia in ART-Naive Subjects Taking Abacavir/Combivir/Nelfinavir, or Lamivudine/Stavudine/NFV (GSK Protocol ESS40002) (October 26, 2001)
In 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from TheBodyPRO.com
- Efficacy and Safety of Switch to 3TC 300 mg QD vs. Continued 3TC 150 mg BID in Subjects with Virologic Suppression on Stable 3TC/d4T/PI Therapy (COLA4005): Final 24-Week Results (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Phosphorylation of Zidovudine, Stavudine, and Abacavir in Peripheral Blood Mononuclear Cells in Treatment-Naive and Treatment-Experienced Patients (February 5, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Lactic Acidosis and Hepatic Steatosis Associated With Use of Stavudine: Report of Four Cases (August 1, 2000)
In Annals of Internal Medicine
- Two Studies Shed Light on Development of d4T Resistance (July 13, 2000)
In The XIII International AIDS Conference, from TheBodyPRO.com
- Studies Suggest Nevirapine Can Be Dosed Either Once or Twice Daily; Effective at Both High and Low Viral Loads (July 11, 2000)
In The XIII International AIDS Conference, from TheBodyPRO.com
- Stavudine for the Treatment of HIV Neurocognitive Impairment (June 29 and July 2, 1998)
In The 12th International AIDS Conference, from TheBodyPRO.com
- A Study in HIV Positive Women of Quadruple Therapy: Nelfinavir, Saquinavir, Stavudine, and Lamivudine (February 4, 1998)
From Seattle Treatment Education Project
- Therapy with d4T plus 3TC Produces Sustained Undetectable Levels of Plasma HIV RNA in Patients Treated with Reverse Transcriptase Inhibitors for 10 Years (February 4, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- A Randomized Double-Blind Study of d4T + ddI versus ZDV + ddI as Initial Treatment in Subjects with CD4 Count <= 500 cells/mm3 (February 4, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Antiviral Activity and Acceptance of Two Different Triple Combinations (February 3, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Combination Therapy With AZT + 3TC + Indinavir vs. d4T + 3TC + Indinavir in Pretreated Patients With Less Than 200 CD4/mm3 (February 3, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- The START Trials (February 3, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- d4T+3TC Versus AZT+3TC: Shattering the Synergy Story (February 3, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- Should AZT and d4T Be Used Together? (February 2, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- The Role of d4T in Initial Combination Regimens (February 2, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- d4T and 3TC Combination Studies Confirm the Effect of the Combination (January 1997)
In The 4th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- ddI + d4T Combination Therapy Proves Effective (January 1997)
In The 4th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
- d4T Plus ddI Antiviral Results (February 1996)
In AIDS Treatment News, from AIDS Treatment News
|
Advertisement
|
Email
Glossary
